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INTERLEUKIN-5 (IL-5) is a key mediator of eosinophilic
inflammation. The biological role of this cytokine in
an allergic airway inflammatory response has been
widely  demonstrated  in  guinea  pigs,  yet  the  inter-
action of guinea pig IL-5 (gpIL-5) with its receptor has
not  been  studied.  Experiments  were  performed  to
quantitate the interaction of gpIL-5 with gpIL-5r and
to compare this affinity with that of hIL-5 and mIL-5
and their cognate receptors. The cross-species affin-
ity and agonist efficacy were evaluated to see if gpIL-
5r had a restricted species reactivity (as is the case
with  mIL-5r)  or  did  not  distinguish  between  IL-5
orthologs (similar to hIL-5r). gpIL-5 was cloned using
mRNA isolated from cells obtained by bronchoalveo-
lar lavage. Recombinant gpIL-5 was expressed in T.ni
insect cells and purified from spent media. Binding
assays were performed using insect cells expressing
hIL-5ra b or gpIL-5ra b 1 as previously described (Cyto-
kine,  12:858–866,  2000)  or  using  B13  cells  which
express  mIL-5r.  The  agonist  potency  and  efficacy
properties of  each  IL-5  ortholog  were  evaluated by
quantitating the proliferative response of human TF-1
cells and murine B13 cells. gpIL-5 bound with high
affinity to recombinant gpIL-5r as demonstrated by
displacing [125I]hIL-5 (Ki = 160 pM). gpIL-5 also bound
to hIL-5r with high affinity (Ki = 750 pM). hIL-5 and
mIL-5 showed similar, high-affinity binding profiles
to both gpIL-5r and hIL-5r. In contrast, gpIL-5 and hIL-
5 did not bind to the mIL-5r as demonstrated by an
inability  to  displace  [125I]mIL-5,  even  at  1000-fold
molar excess. These differences in affinity for IL-5r
orthologs correlated with bioassay results: human TF-
1  cells  showed  roughly  comparable  proliferative
responses  to  guinea  pig,  human  and  murine  IL-5
whereas  murine  B13  cells  showed  a  strong  prefer-
ence for murine over guinea pig and human IL-5 (EC50
= 1.9, 2200 and 720 pM, respectively).  Recombinant
gpIL-5 binds to the gpIL-5r with high affinity, similar
to  that  seen  with  the  human  ligand-receptor  pair.
gpIL-5r  and  hIL-5r  do  not  distinguish  between  the
three  IL-5  orthologs  whereas  mIL-5r  has  restricted
specificity for its cognate ligand.
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Introduction
Activated eosinophils  can  produce  a  wide  array  of
pro-inflammatory mediators and bronchoconstricting
agents (reviewed in refs1,2). The increased numbers of
eosinophils seen in human allergic airways3,4 and the
elevated levels of  eosinophil  products measured  in
bronchoalveolar lavage  (BAL)  from  such  patients3,5
support  the  hypothesis  that eosinophilic  inflamma-
tion  is  an  important  pathogenic  component  of
chronic  asthma.  IL-5  is  important  for  eosinophil
development, mobilization  from  bone  marrow,  and
activation in the allergic airway. Characterization of
this cytokine and an understanding of its role has led
to various therapeutic approaches to block its produc-
tion and or actions (see refs6–8 for reviews).
Guinea  pigs  have  proven  a  valuable  species  for
simulating  certain  aspects  of  airway  inflammation.
For example, both allergen and IL-5 induced release
of  eosinophils  from  guinea  pig  bone  marrow  and
their  accumulation  in  airways  have  been  demon-
strated.9–11 Furthermore, both in vivo and in vitro
studies are commonly performed with guinea pigs to
evaluate  therapeutic  modalities  aimed  at  reducing
the allergic response in humans. Although numerous
studies have described the molecular characteristics
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cognate  receptors,12–16 little  is  known  about  the
guinea  pig  ligand/receptor system.  Guinea  pig  IL-5
(gpIL-5)  has been cloned, expressed and  shown to
induce  airway  eosinophilia  in  guinea  pigs  when
given by tracheal injection.11,17 We recently reported
the cloning and expression of guinea pig IL-5 recep-
tor  a subunit  and  multiple  b subunits.18 We  also
reconstituted  a  high  affinity  gpIL-5rab1 complex
using hIL-5 as ligand. In this report, we extend these
studies  to  show  the  high  affinity  interaction  of
guinea  pig  IL-5  with  its  recombinant  receptor. We
also demonstrate its cross-species affinity and agonist
activity  with  the  human  and  murine  IL-5r  and
compare  these  results  with  those  generated  using
the human and murine orthologs.
Methods
Materials
Murine IL-5 was purchased from R&D Systems (MN).
Dibutyl  phthalate,  phthalic  acid  dinonyl  ester,  and
polyvinylpyrrolidone  were  purchased  from  Sigma
(MO).  Excell  400  media  and  SF900II  media  were
purchased from JRH Biosciences (KS) and GIBCO-BRL
(MD),  respectively. TF-1  cells  were purchased from
ATCC (MD).  B13  cells were kindly  provided by  Dr
Dilniya  Fattah  (GlaxoWelcome  R&D).  [125I]hIL-5,
[125I]mIL-5 and [methyl-H]thymidine were purchased
from NEN (MA).
Cell culture
TF-1  cells  were  maintained  in  RPMI-1640  medium
supplemented  with  10%  fetal  calf  serum,  2 mM
L-glutamine, 10U/ml penicillin and 10mg/ml strepto-
mycin.  A  subclone  (IL-5/TF-1)  displaying  a  greater
proliferative  response  to  human  IL-5  was  selected
following  continuous  culture  in  the  presence  of
human IL-5. Optimal growth conditions were main-
tained by splitting the cultures every 3–4 days with
medium  containing  5ng/ml  IL-5.  B13  cells  were
maintained in  RPMI-1640  with  10%  FBS  containing
5ng/ml murine IL-5.
Cloning guinea pig IL-5 cDNA
Guinea pigs were sensitized by i.p. injection of 5mg
ovalbumin  in  saline  on  day  1  and  then  10mg
ovalbumin  on  day  3.  On  day  14  the  animals  were
challenged with  aerosolized ovalbumin  (1mg/ml  in
saline; 60–90s)  and 24h later BAL was performed.
mRNA was prepared from cells present in the BAL
fluid.  Adapter-ligated  double  stranded  cDNA  was
synthesized  from  mRNA  using  a  Marathon  cDNA
Amplification  kit  (Clontech  Laboratories,  Inc,  CA).
Guinea pig IL-5 was cloned using nested PCR with the
following primers:
Primer #1 was:
59-CTCCGTCCAAAGGTAAAGCTGCACC-39.
Primer #2 was:
59-CCGGAATTCGGATCCTTGTAGCCATGAGGG-
TGCTTCTGC-39.
Primer #3 was:
59-CGCGAAGCTTCCCAAAATCTCTGGATACAA T-
CAGCC-39.
Primer #4 was:
59-CCACATGGTACCCCATTAAAACATGTAC-3 9.
Primer #2 incorporates EcoR1 and BamH1 sites and
Primer #3 incorporates a HindIII site for subcloning
into  the  pFASTBac1  vector  sites.  First  round  PCR
amplification was done using 5ml of a 1:100 dilution
of the product of a 1mg Marathon cDNA reaction as
template. Primers #1 and #4 and Clontech’s Advan-
tage Polymerase mix were used in the first round PCR
amplification which consisted of 30 cycles of 1.5min
at  94°C,  2min  at  55°C  and  2min  at  68°C.  One
microliter of the 1st round PCR product was used as
template  in  a  second  round  reaction  which  used
Primers #2 and #3. Conditions were the same as those
described for  first  round  PCR. The  product  of  the
second  round  PCR  reaction  was  purified  from  an
agarose gel using Qiagen’s Qiaquick gel purification
system and ligated into Novagen’s pT7Blue T-Vector. A
clone  matching  the  published  sequence  (Genbank
Accession  #U34588)  was  identified  and  used  to
prepare expression vectors.
Expressing recombinant proteins using
baculovirus expression system
The gpIL-5 cDNA was subcloned into the pFastBac-1
vector (GIBCO-BRL)  downstream of  the polyhedrin
promoter.  Recombinant  baculovirus  was  obtained
according to the Bac-to-Bac™ Baculovirus Expression
System (Life Technologies, MD) protocols. High titer
viral stocks were prepared in Sf9 cells using SF900II
media.  Optimal  protein  production  was  achieved
using T.ni cells (3 ´ 106 cells/ml) in Excell 400 media
with high titer virus at a multiplicity of infection of
5–10. Supernatants were harvested 72h after infec-
tion and stored at 4°C.
Recombinant gpIL-5rab1 and hIL-5rab complexes
were produced in Sf9 cells as previously described.18
Recombinant hIL-5 was expressed in Sf9 cells using
procedures described by Brown et al.19
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hIL-5  was  purified  by  a  combination  of
Q-Sepaharose, hydoxylapatite and phenyl Sepaharose
column chromatography as described by Johanson et
al.20 gpIL-5 was purified in a single step by negative
selection  ion  exchange  chromatography  on
Q-Sepharose ff19 equilibrated  with  10 mM Tris-HCl,
pH  8.  The  gpIL-5  eluted  in  the  exclusion  volume
while  the  remaining  proteins  were  bound  to  the
column. Contaminating lipids were precipitated by a
1:1 addition of 2M (NH4)2SO4 and then separated by
centrifugation.  The  gpIL-5  preparation  was  then
dialyzed against 50 mM NaHPO4, 150 mM NaCl, pH
7.0 to remove the (NH4)2SO4.
Binding assay
Insect  cells  expressing  either  hIL-5rab or  gpIL-
5rab1 were  processed  for  binding  assays  as  pre-
viously  described.18 Plasma membrane preparations
(5mg aliquots) were incubated with 50pM [125I]hIL-
5  in  assay buffer  consisting of  25 mM Tris,  pH  7.4
and  150 mM  NaCl.  Some  samples  also  received
various concentrations of  unlabeled  human,  guinea
pig, or murine IL-5. The samples were incubated at
23°C  for  1h  and  then  vacuum  filtered  through
96-well  GF/C  filter  plates  (Packard,  Meriden,  CT)
presoaked  in  0.6%  polyvinylpyrrolidone,  0.1%
Tween-20. The  filters  were  washed  with  6  ´ 1ml
aliquots  of  wash  buffer  (10 mM  Tris,  pH  7.4,
100 mM  NaCl,  0.02%  BSA)  and  dried.  Scintillation
fluid  was  added  and  the  amount  of  bound  ligand
measured  using  the TopCount Scintillation  Counter
(Packard). Specific binding was determined by sub-
tracting  the  amount  of  binding  observed  in  the
presence  of  a  100-fold  excess  of  unlabeled  hIL-5.
The  membrane  preparations  containing  hIL-5rab
and  gpIL-5rab1 showed  greater  than  90%  specific
binding  when  incubated  with  50pM  [125I]hIL-5.
Equilibrium  binding  constants  (Kd and  Ki)  and
receptor  densities  (Bmax)  were  determined  using
GraphPad (CA) InPlot software.
B13  cells  were  used  to  measure  binding  of  vari-
ous IL-5 orthologs to the mIL-5r. 1 ´ 106 cells were
incubated  with  50pM  [125I]mIL-5  in  RPMI-1640
media,  10%  FBS,  and  0.02%  sodium  azide.  Some
samples  also  received  various  concentrations  of
unlabeled  murine,  human  or  guinea  pig  IL-5. The
samples  were  incubated  at  23°C  for  1h  and  then
overlaid onto 0.8ml of a phthalate oil mixture (66%
dibutyl  phthalate,  34%  phthalic  acid dinonyl  ester)
in  1.5ml  microcentrifuge  tubes.  The  tubes  were
centrifuged at 13,000 ´ g for 3min, snap frozen in
a dry ice/methanol bath and cut just above the cell
pellet.  Cell-associated  radioactivity  was  determined
using a gamma counter (LKB Pharmacia, NJ).
Proliferation assay
TF-1  and  B13  cells  were  washed  in  PBS  then
resuspended  in  growth  media  in  the  absence  of
serum. After 4h of  serum  starvation the cells  were
seeded at 1.25 ´ 104 cells/well in a 96-well microtitre
plate  with  various  concentrations  of  cytokine  or
media alone. Proliferation was measured by pulsing
cultures during the last 6h of a 72h culture period
with  0.5mCi  of  [methyl-3-H]-thymidine  per  well.
Samples were harvested on a 96-well UniFilter TM-96
GF/C filter plate (Packard, Meriden, CT). MicroScint-
20 scintillation fluid (Packard) was added and incor-
porated [3H]-thymidine measured using the TopCount
Microplate Scintillation Counter system (Packard).
Results
Cloning and expression of guinea pig IL-5
Mansour et al.11 had previously reported the cloning
of gpIL-5 from cells isolated from guinea pig spleen.
We utilized a similar strategy, albeit using cells isolated
by  bronchoalveolar lavage  (BAL)  of ovalbumin-chal-
lenged  animals. This  method  is  known  to  yield  an
enriched  preparation  of  eosinophils  and Th2  cells,
both of which produce IL-5.21–23 A cDNA clone was
obtained which had a predicted amino acid sequence
identical  to  that  published  by  Mansour  et  al.11 A
recombinant  baculovirus  construct  was  generated
containing  this  clone  and  was  used  to  express
recombinant protein in T. ni insect cells.
Recombinant gpIL-5 was purified from the T.ni cell
spent  media  using  essentially  a  single  step  ion
exchange  chromatography  procedure  described  by
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FIG. 1. SDS-PAGE analysis of gpIL-5 and hIL-5. The recombi-
nant proteins were purified  as  described  in Methods. Ali-
quots of gpIL-5 (0.05mg; lane 2) or hIL-5 (0.1mg; lane 3) were
treated with SDS sample buffer in the absence of reducing
agent and then run on a 20% SDS PhastGel (PhastSystem;
Amersham Pharmacia Biotech). The gel was silver stained.
The  bands  in  lane  1  represent  protein  standards,  with
corresponding Mr noted in the margin.Brown et al.19As shown in Fig. 1, the purified protein
migrates at the expected Mr on SDS-PAGE under non-
reducing  conditions,  and  is  consistent  with  the
known homodimeric form of the mature, biologically
active protein. gpIL-5 migrates as a slightly higher Mr
protein compared to human IL-5, presumably due to
an additional glycosylation site (N59) plus a slightly
larger molecular mass of the peptide sequence (13.36
vs 13.15kDa).  In  the  presence  of  reducing  agent,
both  IL-5  preparations  run  at  15–18kDa,  which  is
consistent with the mature protein being comprised
of disulfide-linked monomers (data not shown). The
set of 2–3 bands seen with both preparations have
been observed by others expressing guinea pig and
human IL-5 in insect cells and represents differentially
glycosylated forms of IL-5.11,19,24
Binding to human and guinea pig IL-5r
The IL-5r is a heteromeric complex comprising an a
and b subunit. The human IL-5r a and b subunits were
co-expressed  in  Sf9  cells,  and  plasma  membrane
preparations derived from these cells were used to
reconstitute high affinity binding with [125I]hIL-5 (Fig.
2).18 Analysis of equilibrium binding data indicates a
single  population  of  saturable  binding  sites  with  a
Kd=220pM. This affinity is consistent with that shown
for the binding of hIL-5 to human eosinophils.25–27 A
similar  high  affinity  binding  site  is  observed  with
[125I]hIL-5  and  membrane  preparations  expressing
FIG. 2. Saturation analysis of [
125I]hIL-5 binding to Sf9 membranes expressing hIL-5rab. Plasma membranes from Sf9 cells
infected with baculovirus containing hIL-5rab were incubated with 30pM–5nM [
125I]hIL-5 under standard binding conditions.
Data were analyzed as discussed in Methods and linearized according to the method of Scatchard (inset). Data represent the
mean of triplicate determinations from a typical experiment.
FIG. 3. Inhibition of [
125I]hIL-5 binding to human or guinea
pig IL-5r by IL-5 orthologs. Membranes containing hIL-5rab
(A) or gpIL-5rab1 (B) were incubated with 50pM [
125I]hIL-5 in
the presence of various concentrations of gpIL-5 (. ), hIL-5
(j ), or mIL-5 (s ). Data are expressed as percent of control
binding  and  represent  the  mean±SEM  from  three  experi-
ments performed in triplicate.
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These two preparations were used in displacement
binding assays to determine whether gpIL-5 binds to
gpIL-5rab1 with an affinity similar to that seen with
the human and murine ligand/receptor pairs and also
to  determine  the  relative  affinities  of  guinea  pig,
murine and human IL-5 for the guinea pig and human
IL-5 receptors.
As shown in Fig. 3a, the binding of [125I]hIL-5 to
hIL-5rab was  blocked with an excess  of  unlabeled
hIL-5. The affinity of hIL-5 for hIL-5rab determined by
the displacement assay (Ki=470pM) agrees with that
obtained in the saturation binding experiment descri-
bed  in  Fig.  2  (Kd=220pM).  mIL-5  displaced  the
binding of [125I]hIL-5 to the hIL-5rab preparation, and
did so with a potency (Ki=170pM) similar to that seen
with hIL-5. This is consistent with published results
using  human  eosinophils  as  the  source  of  IL-5r,
indicating that human and murine IL-5 bind to the hIL-
5r with similar affinity.27 Finally, gpIL-5 also bound to
the hIL-5rab with high affinity (Ki=750pM), a value
that was only 2 and 4.4-fold less potent than hIL-5 and
mIL-5, respectively.
A similar set of competitive inhibition experiments
was  performed  with  plasma  membranes  from T.ni
cells expressing gpIL-5rab1 (Fig. 3b). gpIL-5 bound to
it’s  cognate  receptor  with  high  affinity,  as  demon-
strated by blocking the binding of [125I]hIL-5 with a
Ki=160pM. This affinity is similar to that seen with
the human IL-5 ligand/receptor pair. Both murine and
human  IL-5  also  bound  to  this  gpIL-5r  preparation
with high affinity, showing Ki=57 and 97pM, respec-
tively.  Thus,  all  three  IL-5  orthologs  bind  to  the
recombinant  guinea  pig  and  human  IL-5  receptors
with  high  affinities,  and  differ  from  each  other  in
potencies against either receptor preparation by less
than 5-fold. For both preparations of receptors, these
ligands  demonstrated the same rank order potency
with mIL-5>hIL-5>gpIL-5.
Binding to murine IL-5r
B13 cells are a murine Ly1+ pre-B cell line previously
shown  to  express  receptors  for  mIL-5  and  to  pro-
liferate in response to this cytokine.28,29 These cells
were used to determine the relative affinities of the IL-
5 orthologs for the murine receptor. As shown in Fig.
4,  binding  of  [125I]mIL-5  can  be  displaced  with
unlabelled mIL-5 but not hIL-5. Only at the highest
concentration of  hIL-5  tested  was  there  noticeable
displacement of [125I]mIL-5. This is consistent with
previous reports indicating that mIL-5 binds to mIL-5r
with a 400–5000-fold higher affinity than hIL-5.30,31
Interestingly,  the  results  with  gpIL-5  closely  resem-
bled that of hIL-5 rather than mIL-5, i.e. gpIL-5 was
unable to displace [125I]mIL-5 from the mIL-5r. These
results indicate that high affinity binding seen with
mIL-5  is  not  shared  with  all  other  rodent  IL-5
orthologs.
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FIG. 4. Inhibition of [
125I]mIL-5 binding to B13 cells by IL-5
orthologs. Cells were incubated with 50pM [
125I]mIL-5 in the
presence of various concentrations of gpIL-5 (. ), hIL-5 (j ), or
mIL-5 (s ). After 60min, cells were centrifuged through an oil
layer to separate bound from free ligand and the cell pellet
processed as described in Methods. Data are expressed as
percent  of  control  binding  and  represent  the  mean±SEM
from three experiments performed in triplicate.
FIG. 5. Biological activity of IL-5 orthologs on human IL-5/TF-
1 cells and murine B13 cells. Both IL-5/TF-1 (A) and B13 (B)
cells were incubated with increasing concentrations of gpIL-
5 (. ), hIL-5 (j ), or mIL-5 (s ) for 72h and the proliferative
response  measured  by  incorporation  of  [
3H]thymidine  as
described in Methods. Data represent the mean±SEM from
three experiments performed in triplicate.Biological activity of recombinant gpIL-5
The biological activity of gpIL-5 was assessed using a
subclone of human TF-1 cells, (IL-5/TF-1), previously
isolated by long-term culture in hIL-5 and showing a
stronger proliferative response to hIL-5 compared to
the parental line. Similar subclones have been isolated
by others using the same strategy.32 As shown in Fig.
5a, these cells proliferate in response to all three IL-5
orthologs, with gpIL-5 showing slightly  less activity
compared to murine and human IL-5 (EC50= 9.1 vs 1.4
and 2.9pM, respectively). The IL-5 orthologs induce
proliferation at concentrations below their Kd for the
hIL-5r which indicates the presence of spare recep-
tors on these cells. All three IL-5 orthologs produced
the same maximal proliferative response with the IL-
5/TF-1  cells  and  did  so  with  the  same  rank  order
potency observed in the binding experiments.
In contrast to the results with IL-5/TF-1 cells, there
was a substantial difference in the ability of guinea
pig, human and murine IL-5 to induce proliferation of
B13  cells  (Fig.  5b).  mIL-5  was  350–1000-fold  more
potent than human or guinea pig IL-5. This separation
in potency of the biological responses by the murine
receptor  is  consistent  with  the  different  binding
affinities for this receptor. All three IL-5 preparations
had similar intrinsic activities on the mIL-5r, i.e. were
capable  of  eliciting  a  maximal  response,  but  their
relative potencies reflected the differences in affinity
for  this  receptor.  Thus,  only  mIL-5  can  bind  and
activate the mIL-5r with high affinity.
Discussion
Delineating the biological interaction of guinea pig IL-
5 with its receptor would prove useful for compar-
ison to the human ligand/receptor pair, particularly
for relating the molecular properties of hIL-5r antago-
nists to their in vivo profile in guinea pig models of
allergic airway disease. Although gpIL-5 and gpIL-5r
have been cloned and expressed in biologically active
forms,11 their interaction has not been evaluated. In
this paper we describe the binding affinity of recom-
binant gpIL-5 to its receptor and compare its cross-
species  affinity  and  agonist  activity  with  that  of
human and murine IL-5.
As shown in Fig. 3, guinea pig IL-5 bound with high
affinity to recombinant gpIL-5rab1 expressed in Sf9
cells. It bound with a similar high affinity to hIL-5rab,
but did not demonstrate appreciable binding to mIL-
5r  on  B13  cells.  Under  the  conditions used  in  the
mouse  B13  cell  binding  assay,  gpIL-5  showed  no
inhibition  of  binding  at  a  concentration  1000-fold
higher than that required for displacement with mIL-
5, indicating that gpIL-5 has at least 1000-fold lower
affinity for the murine receptor compared to mIL-5.
Human  IL-5  showed  a  binding  profile  that  was
remarkably similar to gpIL-5 across the three receptor
preparations, namely high affinity binding  to hIL-5r
and gpIL-5r, but not mIL-5r. Furthermore, the affinity
of  gpIL-5  for  its cognate receptor is similar  to that
observed with the  human  IL-5 ligand/receptor pair
(Fig. 3).12,33
Recombinant gpIL-5 activated the hIL-5r on human
TF-1  cells,  stimulating  a  maximal  proliferative
response with a potency similar to that seen with hIL-
5.  gpIL-5  was  also  a  full  agonist  for  the  mIL-5r
expressed on B13 cells, but was 1000-fold less potent
than  mIL-5. Thus,  the  biological  potency  of  gpIL-5
correlated with its receptor-binding affinity. A similar
correlation  between  receptor  binding  affinity  and
agonist  potency  was  observed  with  hIL-5  and  is
consistent with previous reports.13,30
Both  murine/human  chimeric  polypeptides  and
alanine  scanning  mutagenesis  have  been  used  to
identify the key charged residues on hIL-5 involved
in binding to the hIL-5r a and b subunits.14,16,31,34,35
These studies have shown that amino acids E88, R90
and  E109  are  involved  in  interactions  with  the
receptor  a chain  while  E12  is  critical  for  b chain
binding and receptor activation. All of these amino
acids are identical for the human, murine and guinea
pig IL-5 orthologs. Site directed mutagenesis studies
also identified the residues on hIL-5 responsible for
the very weak binding affinity to mIL-5r.13 Replacing
two amino acids on hIL-5 with the murine counter-
parts, K84E and N108S, produced a mutant protein
with  a  biological  activity  similar  to  mIL-5.  Single
mutations had biological activities in between mIL-5
and hIL-5. This indicates that both K84 and N108 are
key  residues  on  hIL-5  which  prevent  high  affinity
binding to mIL-5r. Interestingly, gpIL-5 does not bind
to mIL-5r with high affinity, and like hIL-5 contains
asparagine at residue 108. However, gpIL-5 contains
glutamine  at  position  84,  not  lysine  like  hIL-5.
Therefore,  high  affinity  binding  to  mIL-5r  likely
requires  an  acidic  side  chain  (E)  at  residue  84  for
neither  a  basic  side  chain  (K)  nor  an  amide  side
chain (Q) are tolerated. The amino acid sequence of
both rat and gerbil IL-5 are known, and both contain
E84 and S108 like the murine ortholog. Thus, gpIL-5
appears  to  be  an  outlier  within  the  rodent  family,
having  an  amino  acid  sequence  at critical  domains
that  are  more  similar  to  hIL-5  and  demonstrating
cross-species  biological  activity  that  mimics  the
human ortholog.
The data in this report indicates that guinea pig and
human IL-5 are similar in their cross-species profiles:
both  are  relatively  poor  agonists  on  the mIL-5r  yet
bind human and guinea pig IL-5r with high affinity.
Murine IL-5 binds with high affinity to all three IL-5
receptors. These data support the use of guinea pig
models to evaluate the in vivo profile of compounds
designed  to  block  the  interaction of  hIL-5  with  its
cognate receptor. The identification and optimization
of such compounds remains a substantial challenge.
C. W Scott et al.
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